02.01.2015 Views

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Table 4.8.5 Alternatives to intravenous antibiotics.<br />

Author<br />

Year<br />

Reference<br />

Country<br />

Study<br />

design<br />

Population<br />

characteristics<br />

Intervention<br />

Method<br />

Number indi<strong>vid</strong>uals<br />

Control<br />

Number<br />

indi<strong>vid</strong>uals<br />

Results<br />

Withdrawal<br />

Drop outs<br />

Study quality<br />

and relevance<br />

Comments<br />

Desmond<br />

2003<br />

[37]<br />

United<br />

Kingdom<br />

Cohort<br />

study<br />

14 pts with elective<br />

arterial surgery were<br />

prospectively studied.<br />

One surgeon. Study<br />

absorption and systemic<br />

levels of vancomycin.<br />

Serum samples at<br />

30, 60 120, 180<br />

and 730 min in 7 pts<br />

and at 60 and 180 min,<br />

7 pts. In 4 pts samples<br />

from chest drains.<br />

10 pts urinary samples<br />

Iv prophylaxis according to<br />

routine (type not stated). At<br />

closure of sternotomy pts<br />

were randomised to<br />

I1: 500 mg vancomycin powder<br />

I2: 500 mg vancomycin powder<br />

dissolved in 10 mL saline<br />

Serum samples<br />

No difference<br />

between groups<br />

in serum or urinary<br />

levels. Peak serum<br />

levels at 30 min<br />

(mean 2.96 mg/l;<br />

0.99–5.00). At 6 h<br />

1.32 mg/l (0.56–2.17)<br />

T1/2 5 h. Chest drain<br />

levels: 11.3 mg/l<br />

(0.52–29.4)<br />

Moderate<br />

Significant systemic<br />

levels of vancomycin<br />

and in urine for<br />

5 days. Recommended<br />

systemic concentration:<br />

5–10 mg/l.<br />

Small patient study.<br />

Local therapy exposes<br />

patients to systemic<br />

and urinary vancomycin<br />

in significant<br />

doses, but the<br />

exposure below dose<br />

required to inhibit<br />

Staphylococcus aureus<br />

Eklund<br />

2005<br />

[38]<br />

Finland<br />

RCT<br />

557 pts undergoing<br />

elective CABG<br />

during 1 year. Sealed<br />

envelopes. SSI defined.<br />

Follow-up 3 months<br />

I: 10 cm x 10 cm gentamicin<br />

– collagen implant (130 mg gentamicin<br />

and 280 mg collagen)<br />

before wound closure. 2 doses<br />

iv cefuroxime 1.5 g 0 and 6 h.<br />

In addition iv vancomycin<br />

500 mg on two occasions<br />

if hospital stay >72 h<br />

C: No implant 2 doses<br />

iv cefuroxime 1.5 g<br />

and 0 and 6 h in<br />

addition iv vancomycin<br />

500 mg on two<br />

occations if hospital<br />

stay >72 h<br />

Sternal wound infection<br />

I: 11/272 (4.0%)<br />

C: 16/270 (5.9%)<br />

p=0.201<br />

Mediastinitis<br />

I: 3/272 (1.1%)<br />

C: 5/270 (1.9%)<br />

p=0.470<br />

20 pts did<br />

not meet<br />

inclusion<br />

criteria<br />

5 refused to<br />

participate<br />

4 deceased<br />

Moderate<br />

No difference.<br />

Slightly better results<br />

in intervention group.<br />

No side effects. Safe<br />

therapy<br />

Gram positive organisms<br />

accounted for<br />

most infections<br />

The table continues on the next page<br />

388 antibiotikaprofylax <strong>vid</strong> <strong>kirurgiska</strong> <strong>ingrepp</strong> KAPITEL 4 • den systematiska litteraturöversikten<br />

389

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!